• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Chimeric Antigen Receptor Therapy.

作者信息

June Carl H, Sadelain Michel

机构信息

From the Center for Cellular Immunotherapies, Perelman School of Medicine, Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia (C.H.J.); and the Center for Cell Engineering, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York (M.S.).

出版信息

N Engl J Med. 2018 Jul 5;379(1):64-73. doi: 10.1056/NEJMra1706169.

DOI:10.1056/NEJMra1706169
PMID:29972754
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7433347/
Abstract
摘要

相似文献

1
Chimeric Antigen Receptor Therapy.嵌合抗原受体疗法
N Engl J Med. 2018 Jul 5;379(1):64-73. doi: 10.1056/NEJMra1706169.
2
Functional design of chimeric T-cell antigen receptors for adoptive immunotherapy of cancer: architecture and outcomes.嵌合 T 细胞抗原受体的功能设计用于癌症的过继免疫疗法：结构和结果。
Anticancer Res. 2012 Jun;32(6):2377-83.
3
CAR therapy: the CD19 paradigm.嵌合抗原受体（CAR）疗法：CD19范例
J Clin Invest. 2015 Sep;125(9):3392-400. doi: 10.1172/JCI80010. Epub 2015 Sep 1.
4
What CAR Will Win the CD19 Race?什么嵌合抗原受体（CAR）将赢得 CD19 之战？
Mol Cancer Ther. 2019 Mar;18(3):498-506. doi: 10.1158/1535-7163.MCT-18-1070.
5
Chimaeric antigen receptor T-cell therapy for tumour immunotherapy.用于肿瘤免疫治疗的嵌合抗原受体T细胞疗法。
Biosci Rep. 2017 Jan 27;37(1). doi: 10.1042/BSR20160332. Print 2017 Feb 28.
6
Retargeting CD19 Chimeric Antigen Receptor T Cells via Engineered CD19-Fusion Proteins.通过工程化的 CD19 融合蛋白重新靶向 CD19 嵌合抗原受体 T 细胞。
Mol Pharm. 2019 Aug 5;16(8):3544-3558. doi: 10.1021/acs.molpharmaceut.9b00418. Epub 2019 Jul 15.
7
CART trials are going ahead.嵌合抗原受体T细胞（CART）试验正在进行中。
Sci China Life Sci. 2017 Nov;60(11):1276-1279. doi: 10.1007/s11427-017-9198-1. Epub 2017 Oct 26.
8
Treatment of solid tumors with chimeric antigen receptor-engineered T cells: current status and future prospects.嵌合抗原受体修饰 T 细胞治疗实体瘤：现状与展望。
Sci China Life Sci. 2016 Apr;59(4):360-9. doi: 10.1007/s11427-016-5025-6. Epub 2016 Mar 11.
9
CARTs for Solid Tumors: Feasible or Infeasible?嵌合抗原受体 T 细胞疗法治疗实体瘤：可行还是不可行？
Oncol Res Treat. 2017;40(9):540-546. doi: 10.1159/000477095. Epub 2017 Aug 17.
10
Allogeneic chimeric antigen receptor-modified cells for adoptive cell therapy of cancer.异体嵌合抗原受体修饰细胞用于过继细胞疗法治疗癌症。
Expert Opin Biol Ther. 2014 Jul;14(7):947-54. doi: 10.1517/14712598.2014.900540. Epub 2014 Mar 24.

引用本文的文献

1
Pleural Mesothelioma: Pathogenesis, Diagnosis, Treatment, Prognosis, and Survival.胸膜间皮瘤：发病机制、诊断、治疗、预后及生存情况
MedComm (2020). 2025 Sep 1;6(9):e70327. doi: 10.1002/mco2.70327. eCollection 2025 Sep.
2
Advancing gene editing therapeutics: Clinical trials and innovative delivery systems across diverse diseases.推进基因编辑疗法：针对多种疾病的临床试验和创新递送系统
Mol Ther Nucleic Acids. 2025 Aug 5;36(3):102666. doi: 10.1016/j.omtn.2025.102666. eCollection 2025 Sep 9.
3
Chimeric anti-HLA antibody receptor engineered human regulatory T cells suppress alloantigen-specific B cells from pre-sensitized transplant recipients.嵌合抗HLA抗体受体工程化人调节性T细胞可抑制预致敏移植受者的同种抗原特异性B细胞。
Front Immunol. 2025 Aug 15;16:1601385. doi: 10.3389/fimmu.2025.1601385. eCollection 2025.
4
CAR-T therapy: pioneering a new era in the treatment of autoimmune diseases.嵌合抗原受体T细胞（CAR-T）疗法：开创自身免疫性疾病治疗的新时代。
Front Immunol. 2025 Aug 13;16:1625166. doi: 10.3389/fimmu.2025.1625166. eCollection 2025.
5
CAR T-cell therapy in autoimmune diseases: a promising frontier on the horizon.自身免疫性疾病中的嵌合抗原受体T细胞疗法：一个充满前景的前沿领域。
Front Immunol. 2025 Aug 12;16:1613878. doi: 10.3389/fimmu.2025.1613878. eCollection 2025.
6
Glioblastoma: From Pathophysiology to Novel Therapeutic Approaches.胶质母细胞瘤：从病理生理学到新型治疗方法
Biomedicines. 2025 Aug 12;13(8):1963. doi: 10.3390/biomedicines13081963.
7
Introducing CAR-T Therapy in Kazakhstan: Establishing Academic-Scale Lentiviral Vector and CAR-T Cell Production.在哈萨克斯坦引入嵌合抗原受体T细胞（CAR-T）疗法：建立学术规模的慢病毒载体和CAR-T细胞生产体系。
Biomolecules. 2025 Aug 14;15(8):1166. doi: 10.3390/biom15081166.
8
Molecular Insights into Tumor Immunogenicity.肿瘤免疫原性的分子见解
Curr Issues Mol Biol. 2025 Aug 11;47(8):641. doi: 10.3390/cimb47080641.
9
Optimization and validation of the international metabolic prognostic index for CD19 CAR-T in large B-cell lymphoma.大B细胞淋巴瘤中CD19嵌合抗原受体T细胞疗法的国际代谢预后指数的优化与验证
Blood Cancer J. 2025 Aug 26;15(1):144. doi: 10.1038/s41408-025-01338-1.
10
Conversion of natural cytokine receptors into orthogonal synthetic biosensors.将天然细胞因子受体转化为正交合成生物传感器。
Nat Chem Biol. 2025 Aug 22. doi: 10.1038/s41589-025-01986-1.

本文引用的文献

1
CAR T cell immunotherapy for human cancer.嵌合抗原受体 T 细胞免疫疗法治疗人类癌症。
Science. 2018 Mar 23;359(6382):1361-1365. doi: 10.1126/science.aar6711.
2
Activity of Mesothelin-Specific Chimeric Antigen Receptor T Cells Against Pancreatic Carcinoma Metastases in a Phase 1 Trial.嵌合抗原受体 T 细胞针对 1 期试验中胰腺癌细胞转移的间皮素特异性活性。
Gastroenterology. 2018 Jul;155(1):29-32. doi: 10.1053/j.gastro.2018.03.029. Epub 2018 Mar 20.
3
Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia.急性淋巴细胞白血病中CD19嵌合抗原受体疗法的长期随访
N Engl J Med. 2018 Feb 1;378(5):449-459. doi: 10.1056/NEJMoa1709919.
4
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia.替沙格赛定用于治疗儿童和年轻成人B细胞淋巴细胞白血病
N Engl J Med. 2018 Feb 1;378(5):439-448. doi: 10.1056/NEJMoa1709866.
5
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma.阿基仑赛注射液嵌合抗原受体T细胞疗法治疗难治性大B细胞淋巴瘤
N Engl J Med. 2017 Dec 28;377(26):2531-2544. doi: 10.1056/NEJMoa1707447. Epub 2017 Dec 10.
6
Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas.难治性B细胞淋巴瘤中的嵌合抗原受体T细胞
N Engl J Med. 2017 Dec 28;377(26):2545-2554. doi: 10.1056/NEJMoa1708566. Epub 2017 Dec 10.
7
CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy.CD22 靶向 CAR T 细胞可诱导对 CD19 靶向 CAR 免疫疗法初治或耐药的 B-ALL 缓解。
Nat Med. 2018 Jan;24(1):20-28. doi: 10.1038/nm.4441. Epub 2017 Nov 20.
8
Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells.嵌合抗原受体 T 细胞过继免疫治疗后神经毒性中的血管内皮细胞激活和血脑屏障破坏。
Cancer Discov. 2017 Dec;7(12):1404-1419. doi: 10.1158/2159-8290.CD-17-0698. Epub 2017 Oct 12.
9
Integrating Proteomics and Transcriptomics for Systematic Combinatorial Chimeric Antigen Receptor Therapy of AML.整合蛋白质组学和转录组学用于急性髓系白血病的系统性组合嵌合抗原受体疗法
Cancer Cell. 2017 Oct 9;32(4):506-519.e5. doi: 10.1016/j.ccell.2017.09.004.
10
Augmentation of Antitumor Immunity by Human and Mouse CAR T Cells Secreting IL-18.人源化和鼠源嵌合抗原受体 T 细胞分泌白细胞介素-18 增强抗肿瘤免疫
Cell Rep. 2017 Sep 26;20(13):3025-3033. doi: 10.1016/j.celrep.2017.09.002.